As filed with the Securities and Exchange Commission on March 11, 201410, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

Or

For the fiscal year ended December 31, 20132014

Or

For the transition period from              to             

Or

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

Indicate the number of outstanding shares of each of the issuers’ classes of capital or common stock as of December 31, 2013:2014:

Indicate by check mark if the registrants are well-known seasoned issuers, as defined in Rule 405 of the Securities Act.

Yes                þ                 No                ¨

If this report is an annual or transition report, indicate by check mark if the registrants are not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes                ¨                No                þ

Indicate by check mark whether the registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) have been subject to such filing requirements for the past 90 days.

Yes                þ                No                ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes                ¨                No                ¨

Indicate by check mark whether the registrants are large accelerated filers, accelerated filers, or non-accelerated filers. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  þ                            Accelerated filer  ¨                            Non-accelerated filer  ¨

Indicate by check mark which basis of accounting the registrants have used to prepare the financial statements included in this filing.

¨    US GAAP             þ    International Financial Reporting Standards as issued by the International Accounting Standards Board            ¨    Other

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrants have elected to follow:

Item  17        ¨                     Item 18        ¨

If this is an annual report, indicate by check mark whether the registrants are shell companies (as defined in Rule 12b-2 of the Exchange Act).

Yes                ¨                  No                þ

TABLE OF CONTENTS

THIS PAGE INTENTIONALLY BLANK

GENERAL

Reed Elsevier PLC and Reed Elsevier NV conductconducted their business through two jointly owned companies during 2014, Reed Elsevier Group plc and Elsevier Reed Finance BV. Reed Elsevier PLC and Reed Elsevier NV have retained their separate legal identities. Effective February 25, 2015, Reed Elsevier PLC and national identities. “Reed Elsevier”Reed Elsevier NV transferred their direct ownership interests in Elsevier Reed Finance BV to their jointly-owned company Reed Elsevier Group plc and named this newly-combined single group entity RELX Group plc. As a result, RELX Group plc now holds all Reed Elsevier businesses, subsidiaries and financing activities. Further information is not a legal entity but a collective referenceprovided on pages 23 to 24. As used in this Annual Report on Form 20-F, the separate legal entities ofterms the “Group,” “RELX,” the “combined businesses,” “we,” “our” or “us” refer collectively, to Reed Elsevier PLC, Reed Elsevier NV, Reed ElsevierRELX Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures. The businesses of all of the entities comprising Reed Elsevier are collectively referred to in this annual report as “Reed Elsevier”, and the financial statements of the combined businesses are referred to herein as the “combined financial statements”. In this annual report, references to “we”, “our”, or “us”Additional terms are to alldefined in the Glossary of the entities comprising Reed Elsevier.Terms on pages S-1 and S-2.

In this annual report, references to US dollars, $ and ¢ are to US currency; references to sterling, £, pence or p are to UK currency; references to euro and € are to the currency of the European Economic and Monetary Union.

Statements regarding our competitive position included herein were obtained from internal surveys, market research, publicly available information and industry publications. While we believe that the market research, publicly available information and industry publications we use are reliable, we have not independently verified market and industry data fromthird-party sources. Moreover, while we believe our internal surveys are reliable, they have not been verified by any independent source.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This document contains or incorporates by reference a number of forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, with respect to:

We consider any statements that are not historical facts to be “forward-looking statements”. These statements are based on the current expectations of the management of our businesses and are subject to risks and uncertainties that could cause actual results or outcomes to differ from those expressed in any forward-looking statement. These differences could be material; therefore, you should evaluate forward-looking statements in light of various important factors, including those set forth or incorporated by reference in this document.

Important factors that could cause actual results to differ materially from estimates or forecasts contained in the forward looking statements include, among others:

The terms “estimate”, “project”, “plan”, “intend”, “expect”, “should be”, “will be”, “believe”, “trends” and similar expressions identify forward-looking statements. These forward-looking statements are found at various places throughout this annual report and the other documents incorporated by reference in this annual report.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this annual report. WeExcept as may be required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this annual report or to reflect the occurrence of unanticipated events.

PART I

ITEM 3: KEY INFORMATION

SELECTED FINANCIAL DATA

REED ELSEVIERTHE GROUP

The selected combined financial data for Reed Elsevierthe Group should be read in conjunction with, and is qualified by, the combined financial statements included in this annual report. In addition, as separate legal entities, Reed Elsevier PLC and Reed Elsevier NV prepare separate consolidated financial statements which reflect their respective shareholders’ economic interests in Reed Elsevierthe Group accounted for on an equity basis.

The combined financial statements are prepared in accordance with accounting policies that are in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and as adopted by the European Union (“EU”). The selected financial data for Reed Elsevierthe Group (in £) as at and for the years ended December 31, 2014, 2013 2012 and 20112012 set out below has been extracted or derived from the audited combined financial statements, included herein. The selected financial data for Reed Elsevierthe Group as at and for the years ended December 31, 20102011 and 20092010 set out below has been extracted or derived from our audited financial statements, which are not included herein, retrospectivelyand restated for the adoption of International Accounting Standard (“IAS”) 19 Employee Benefits (revised)., which was adopted in the year ended December 31, 2013.

Combined Income Statement Data⁽¹⁾

Combined Statement of Financial Position Data⁽¹⁾

2011: nil; 2010: nil; 2009: £177 million); nil in respect of exceptional restructuring costs (2012:(2013: nil; 2012: nil; 2011: nil;

2010: £57 million; 2009: £182 million); £43£30 million in respect of acquisition related costs (2012:(2013: £43 million; 2012: £21 million; 2011: £52 million; 2010: £50 million; 2009: £48 million); nil in respect of the share of joint ventures’ profit on disposals (2012:(2013: nil; 2012: nil; 2011: £1 million credit;million; 2010: nil; 2009: nil) and £12£21 million in respect of taxation in joint ventures (2012:(2013: £12 million; 2012: £5 million; 2011: £11 million; 2010: £9 million; 2009: £8 million). Impairment charges in 2009 relate principally to Business Information. Exceptional restructuring costs in 2010 relate only to the restructuring of the Risk & Business Information business and in 2009 relate to the exceptional restructuring programmes across Reed Elsevier.business.

REED ELSEVIER PLC

The selected financial data for Reed Elsevier PLC should be read in conjunction with, and is qualified in its entirety by, the consolidated financial statements of Reed Elsevier PLC included in this annual report. The results and financial position of Reed Elsevier PLC reflect the 52.9% economic interest of Reed Elsevier PLC’s shareholders in Reed Elsevier,the Group, after taking account of results arising in Reed Elsevier PLC and its subsidiaries. These interests have been accounted for on an equity basis.

The consolidated financial statements are prepared in accordance with accounting policies that are in conformity with IFRS as issued by the IASB and as adopted by the EU. The selected financial data for Reed Elsevier PLC (in £) as at and for the years ended December 31, 2014, 2013 2012 and 20112012 set out below has been extracted or derived from the audited consolidated financial statements, included herein. The selected financial data for Reed Elsevier PLC as at and for the years ended December 31, 20102011 and 20092010 set out below has been extracted or derived from our audited financial statements, which are not included herein, retrospectivelyand restated for the adoption of IAS19 Employee Benefits (revised)., which was adopted in the year ended December 31, 2013.

Dividends paid in the year, in amounts per ordinary share, comprise a 20122013 final dividend of 17.0p17.95p and 20132014 interim dividend of 6.65p7.0p giving a total of 23.65p.24.95p. The directors of Reed Elsevier PLC have proposed a 20132014 final dividend of 17.95p (2012:19.0p (2013: 17.95p; 2012: 17.0p; 2011: 15.9p; 2010: 15.0p; 2009: 15.0p), giving a total ordinary dividend in respect of the financial year of 24.60p (2012:26.0p (2013: 24.6p; 2012: 23.0p; 2011: 21.55p; 2010: 20.4p; 2009: 20.4p).

REED ELSEVIER NV

The selected financial data for Reed Elsevier NV should be read in conjunction with, and is qualified in its entirety by, the consolidated financial statements of Reed Elsevier NV included in this annual report. The results and financial position of Reed Elsevier NV reflect the 50% economic interest of Reed Elsevier NV’s shareholders in Reed Elsevier.the Group. These interests are accounted for on an equity basis.

The consolidated financial statements are prepared in accordance with accounting policies that are in conformity with IFRS as issued by the IASB and as adopted by the EU. The selected financial data for Reed Elsevier NV (in €) as at and for the years ended December 31, 2014, 2013 2012 and 20112012 set out below has been extracted or derived from the audited consolidated financial statements, included herein. The selected financial data for Reed Elsevier NV as at and for the years ended December 31, 20102011 and 20092010 set out below has been extracted or derived from our audited financial statements, which are not included herein, retrospectivelyand restated for the adoption of IAS19 Employee Benefits (revised)., which was adopted in the year ended December 31, 2013.

(4)

Dividends paid in the year, in amounts per ordinary share, comprise a 20122013 final dividend of €0.337€0.374 and 20132014 interim dividend of €0.132€0.151 giving a total of €0.469.€0.525. The directors of Reed Elsevier NV have proposed a 20132014 final dividend of €0.374 (2012:€0.438 (2013: €0.374; 2012: €0.337; 2011: €0.326; 2010: €0.303; 2009: €0.293)€0.303), giving a total ordinary dividend in respect of the financial year of €0.506 (2012:€0.589 (2013: €0.506; 2012: €0.467; 2011: €0.436; 2010: €0.412; 2009: €0.400)€0.412).

EXCHANGE RATES

For a discussion of the impact of currency fluctuations on Reed Elsevier’sthe Group’s combined results of operations and combined financial position, see “Item 5: Operating and Financial Review and Prospects”.

The following tables illustrate, for the periods and dates indicated, certain information concerning the Noon Buying Rate for pounds sterling expressed in US dollars per £1.00 and for the euro expressed in US dollars per €1.00. The exchange rate on February 28, 201427, 2015 was £1.00 = $1.68$1.54 and €1.00 = $1.38.$1.12.

US dollars per £1.00 — Noon Buying Rates

US dollars per €1.00 — Noon Buying Rates

Noon Buying Rates have not been used in the preparation of the Reed Elsevier combined financial statements, the Reed Elsevier PLC consolidated financial statements or the Reed Elsevier NV consolidated financial statements but have been used for certain convenience translations where indicated.

RISK FACTORS

The key materialprincipal risks tofacing our business are included below. Additional risks not presently known to us or that we currently deem immaterial may also impair our business.

We operate in a highly competitive environment that is subject to rapid change.

Our businesses operate in highly competitive markets. These markets continue to change in response to technological innovations, changing legislation,legislative and regulatory changes, the entrance of new competitors, and other factors. We cannot predict with certainty the changes that may occur and the effect of those changes on the competitiveness of our businesses. In particular, the means of delivering our products and services, and the products and services themselves, may be subject to rapid technological and other changes. We cannot predict whether technological innovations, changing legislation or other factors will, in the future, make some of our products wholly or partially obsolete or less profitable. Failure to anticipate market trends could impact the competitiveness of our products and services and consequently adversely affect our revenue and profit.

We cannot assure you that there will be continued demand for our products and services.

Our businesses are dependent on the continued acceptance by our customers of our products and services and the value placed on them. We cannot predict whether there will be changes in the future, either in the market demand or from the actions of competitors, which will affect the acceptability of products, services and prices to our customers. Failure to meet evolving customer needs could impact demand for our products and services and consequently adversely affect our revenue.

Fluctuations in exchange rates may affect our reported results.

Our financial statements are expressed in pounds sterling and euros and are, therefore, subject to movements in exchange rates on the translation of the financial information of businesses whose operational currencies are other than our reporting currencies. The United States is our most important market and, accordingly, significant fluctuations in US dollar exchange rates can significantly affect our reported results and financial position from year to year. In addition, in some of our businesses we incur costs in currencies other than those in which revenues are earned. The relative movements between the exchange rates in the currencies in which costs are incurred and the currencies in which revenues are earned can significantly affect the results of those businesses.

Current and future economic, political and market forces, and dislocations beyond our control may adversely affect demand for our products and services.

The demand for our products and services may be impacted by factors that are beyond our control, including macro economic, political and market conditions, the availability of short term and long term funding and capital and the level of volatility of interest rates, currency exchange rates and inflation. The United States, Europe and other major economies have recentlyin recent years undergone a period of severe economic turbulence, and the global economic environment has recently been less favourable than in prior years and this may continue into the future. Any one or more of these factors may contribute to reduced activity by our customers, may result in a reduction of demand for our products and services, and may adversely affect suppliers and third parties to whom we have outsourced business activities.

Changes in tax laws or uncertainty over their application and interpretation may adversely affect our reported results.

Our businesses operate globally and our earnings are subject to taxation in many differing jurisdictions and at differing rates. We seek to organise our affairs in a tax efficient manner, taking account of the jurisdictions in which we operate. However, tax laws that apply to our businesses may be amended or interpreted differently by the relevant authorities, which could adversely affect our reported results.

Changes in regulation of information collection and use could adversely affect our business.

Legal regulation relating to internet communications, data protection, e-commerce, direct marketing, credit scoring and digital advertising, privacy, information governance and use of public records is becoming more prevalent.prevalent worldwide. Existing and proposed legislation and regulations, including changes in the manner in which such legislation and regulations are interpreted by courts in the United States, the European Union and other jurisdictionsregulators may impose limits on our collection and use of certain kinds of information about individuals and our ability to communicate such information effectively with our customers. For example, many of the products offered by Risk Solutions& Business Information are governed bysubject to regulation under the US Fair Credit Reporting Act (“FCRA”), GrahamGramm Leach Bliley Act (“GLBA”), Drivers Privacy Protection Act (“DPPA”) and related state laws. Certain of these laws further provide for statutory penalties and attorneys fees for non-compliance. We are unable to predict in what form laws and regulations will be adopted or modified or how they will be construed by the courts and regulators, or the extent to which any such laws or interpretation changes might adversely affect our business.

Changes in provision of third party information to us could adversely affect our businesses.

A number of our businesses rely extensively upon content and data from external sources. Data is obtained from public records, governmental authorities, customers and other information companies, including competitors. In the case of public records, including social security number data which are obtained from public authorities, our access is governed by law. We also obtain the credit header data in our databases from consumer credit reporting agencies. The disruption or loss of data sources, either because of changes in the law or because data suppliers decide not to supply them, could adversely affect our products and services.

Our business, operations and reputation could be adversely affected by a failure to comply with FTC Settlement Orders.

Through our Risk Solutions& Business Information business in the United States, we are party to two consent orders and two subsequent related supplemental orders (the “FTC Settlement Orders”) embodying settlements with the US Federal Trade Commission (“FTC”) that resolved FTC investigations into our compliance with federal laws governing consumer information security and related issues, including certain fraudulent data access incidents. We also entered into an Assurance of Voluntary Compliance and Discontinuance (the “AVC”) with the Attorneys General of 43 states and the District of Columbia in connection with one such FTC investigation. The FTC Settlement Orders and the AVC require us to institute and maintain information security, verification, credentialing, audit and compliance, and reporting and record retention programmes and to obtain an assessment from a qualified, independent third party every two years for twenty years (with the FTC having the right to extend such twenty-year period by up to two additional biennial assessment periods) to ensure that our performance under these information security programmes complies with the FTC Settlement Orders. Failure to comply with the FTC Settlement Orders and the AVC could result in civil penalties and adversely affect our business, operations and reputation.

Breaches of our data security systems or other unauthorised access to our databases could adversely affect our business and operations.

Our businesses provide customers with access to database information such as case law, treatises, journals, and publications as well as other data. Our Risk Solutions businessSome of our businesses also providesprovide authorised customers with access to public records and other information on US individuals made available in accordance with applicable privacy laws and regulations. There are persons who try to breach our data security systems or gain other unauthorised access to our databases in order to misappropriate such information for potentially fraudulent purposes and we have previously disclosed incidents of such unauthorised access. Because the techniques used by such persons change frequently, we may be unable to anticipate or protect against the threat of breaches of data security or other unauthorised access. Breaches of our data security systems or other unauthorised access to our databases could damage our reputation and expose us to a risk of loss or litigation and possible liability, as well as increase the likelihood of more extensive governmental regulation of these activities in a way that could adversely affect this aspect of our business.

Changes in levels of government funding of, or spending by, academic institutions may adversely affect demand for the products and services of our scientific, technical and medical (“STM”) businesses.

The principal customers for the information products and services offered by our STM publishing businesses are academic institutions, which fund purchases of these products and services from limited budgets that may be sensitive to changes in private and governmental sources of funding. Accordingly, any decreases in budgets of academic institutions or changes in the spending patterns of academic institutions could negatively impact our business and revenues.

Our intellectual property rights may not be adequately protected under current laws in some jurisdictions, which may adversely affect our results and our ability to grow.

Our products and services are largely comprised of intellectual property content delivered through a variety of media, including online, journals books, compact discs, and online, including the internet.books. We rely on trademark, copyright, patent, trade secret and other intellectual property laws to establish and protect our proprietary rights in these products and services. However, we cannot assure you that our proprietary rights will not be challenged, limited, invalidated or circumvented. Despite trademark and copyright protection and similar intellectual property protection laws, third parties may be able to copy, infringe or otherwise profit from our proprietary rights without our authorisation. These unauthorised activities may be facilitated by the internet.

In addition, whilst there is now certain internet-specific copyright legislation in the United States and in the European Union, there remains significant uncertainty as to the date from which such legislation will be enforced and the form copyright law regulating digital content may ultimately take. In several jurisdictions, including the United States, Australia and the European Union, copyright laws are increasingly coming under legal review. These factors create additional challenges for us in protecting our proprietary rights in content delivered through the internet and electronic platforms. Moreover, whilst non-copyrightable databases are protected in many circumstances by law in the European Union, there is no equivalent legal protection in the United States.

We may be unable to implement and execute our strategic and business plans if we cannot maintain high-quality management.

The implementation and execution of our strategic and business plans depend on our ability to recruit, motivate and retain high-quality people. We compete globally and across business sectors for talented management and skilled individuals, particularly those with technology and data analytics capabilities. An inability to recruit, motivate or retain such people could adversely affect our business performance.

We may not realise all of the future anticipated benefits of acquisitions.

We regularly make small business acquisitions to strengthen our portfolio. Whilst our acquisitions are made within the framework of our overall strategy, which emphasises organic development, we cannot assure you we will be able to generate the anticipated benefits such as revenue growth synergies and/or cost savings associated with these acquisitions. Failure to realizerealise the anticipated benefits of acquisitions could adversely affect our return on invested capital and financial condition.

We cannot assure you whether our substantial investment in electronic product and platform initiatives will produce satisfactory, long term returns.

We are investing significant amounts to develop and promote electronic products and platforms. The provision of electronic products and services is very competitive and we may experience difficulties developing this aspect of our business due to a variety of factors, many of which are beyond our control. These factors may include competition from comparable and new technologies and changes in regulation.

Our businesses may be adversely affected if their electronic delivery platforms, networks or distribution systems experience a significant failure or interruption.

Our businesses are dependent on electronic platforms and distribution systems, primarily the internet, for delivery of their products and services. From time to time we have experienced verifiable attacks on our platforms and systems by unauthorised parties. To date such attacks have not resulted in any material damage to us, however, our businesses could be adversely affected if their electronic delivery platforms and networks experience a significant failure, interruption or security breach.

Our businesses may be adversely affected by the failure of third parties to whom we have outsourced business activities.

Our organisational and operational structures are dependent on outsourced and offshored functions. Poor performance or the failure of third parties to whom we have outsourced business functions could adversely affect our business performance, reputation and financial condition.

Our scientific, technical and medical primary publications could be adversely affected by changes in the market.

Our STM primary publications, like those of most of our competitors, are published on a paid subscription basis. There is continued debate in government, academic and library communities, which are the principal customers for our STM publications, regarding, whetherto what extent such publications should be funded instead through fees charged to authors or authors’ funders and/or made freely available in some form after a period following publication. If these methods of STM publishing are widely adopted or mandated, it could adversely affect our revenue from our paid subscription publications.

Spending by companies on advertising and other marketing activities, which comprises a significant portion of our revenue, has historically been cyclical.

In 2013 4%2014 2% of our revenue was derived from advertising. In Business Information, 21% of revenue was derived from advertising in 2013 compared with 30% in 2012. Total advertising revenues for our businesses in 20132014 were £240£135 million compared with £350£240 million in 2012.2013. Traditionally, spending by companies on advertising and other marketing activities has been cyclical, with companies spending significantly less on advertising in times of economic slowdown or turbulence. In addition, there has been a structural shift of advertising and lead generation to Google and other search engines.

Exhibitions is similarly affected by cyclical pressures on spending by companies. Additionally, participation and attendance at exhibitions is affected by the availability of exhibition venues and the propensity of exhibitors and attendees to travel. Our results could be adversely affected if the availability of venues or the demand from exhibitors and attendees were reduced, for example due to international security or public health concerns or acts of terrorism or war.

Changes in the market values of defined benefit pension scheme assets and in the assumptions used to value defined benefit pension scheme obligations may adversely affect our businesses.

We operate a number of pension schemes around the world. Historically, the largest schemes have been local versions of the defined benefit type in the United Kingdom, the United States and the Netherlands. The assets and obligations associated

with defined benefit pension schemes are sensitive to changes in the market values of assets and the market related assumptions used to value scheme liabilities. In particular, declines in asset values, or increases in pension scheme liabilities, due to adverse changes to asset values,in discount rates, inflation or inflationmortality assumptions could increase future pension costs and funding requirements.

Our impairment analysis of goodwill and indefinite lived intangible assets incorporates various assumptions which are highly judgemental. If these assumptions are not realised, we may be required to recognise a charge in the future for impairment.

As at December 31, 2013,2014, goodwill on the combined statement of financial position amounted to £4,576£4,981 million and intangible assets with an indefinite life amounted to £347£369 million. We conduct an impairment test at least annually, which involves a comparison of the carrying value of goodwill and indefinite lived intangible assets by cash generating unit with estimated values in use based on latest management cash flow projections. The assumptions used in the estimation of value in use are, by their very nature, highly judgemental, and include profit growth of the business over a five year forecast period, the long term growth rate of the business thereafter, and related discount rates. There is no guarantee that our businesses will be able to achieve the forecasted results which have been included in the impairment tests and impairment charges may be required in future periods if we are unable to meet these assumptions.

Our borrowing costs and access to capital may be adversely affected if the credit ratings assigned to our debt are downgraded.

Our outstanding debt instruments are, and any of our future debt instruments may be, publicly rated by independent rating agencies such as Moody’s Investors Service Inc., Standard & Poor’s Rating Services and Fitch Ratings. A rating is based upon information furnished by us or obtained by the relevant rating agency from its own sources and from publicly available information and is subject to revision, suspension or withdrawal by the rating agency at any time. Rating agencies may review the assigned ratings due to developments that are beyond our control. Factors cited as a basis for a ratings downgrade or an assignment of a negative outlook could include the macro economic environment and the level of our indebtedness as a consequence of an acquisition. If the ratings of our debt are downgraded in the future, our borrowing costs and access to capital may be adversely affected.

Breaches of generally accepted ethical business standards or applicable statutes concerning bribery could adversely affect our reputation and financial condition.

As a world leading provider of professional information solutions to the science, technicalSTM, Risk & Business Information, Legal and medical, risk, legal and business sectors,Exhibitions markets, we are expected to adhere to high standards of independence and ethical conduct. Whilst our employees are expected to abide by the Reed Elsevierour Code of Ethics and Business Conduct, employees may still fail to abide by its guidelines relating to anti-bribery and principled business conduct. Similarly, whilst our major suppliers are expected to abide by our Supplier Code of Conduct, suppliers may still fail to abide by its guidelines relating to anti-bribery and principled business conduct. A breach of generally accepted ethical business standards or applicable statuesstatutes concerning bribery by our employees or our suppliers could adversely affect our business performance, reputation and financial condition.

Failure to manage our environmental impact could adversely affect our businesses.

Our businesses have an impact on the environment, principally through the use of energy and water, waste generation and, in our supply chain, through our paper use and print and production technologies. Whilst we are committed to reducing these impacts by limiting resource use and by efficiently employing sustainable materials and technologies, we cannot assure you that these efforts and expenditures incurred by us in order to comply with either new environmental legislation and regulations, new interpretations or existing laws and regulations or more rigorous enforcement of such laws and regulations will not adversely impact our businesses or reputation.

ITEM 4: INFORMATION ON REED ELSEVIERTHE GROUP

HISTORY AND DEVELOPMENT

Corporate structureIntroduction

Reed Elsevier came into existenceNV was originally incorporated in January1880 and Reed Elsevier PLC in 1903. In 1993 whenthey contributed their respective businesses to two jointly owned companies, Reed Elsevier Group plc and Elsevier Reed Finance BV. The parent companies, Reed Elsevier PLC and Reed Elsevier NV, contributed their respective businesses to two jointly-owned companies,are separate, publicly-held entities. Reed Elsevier PLC’s ordinary shares are listed in London and New York, and Reed Elsevier NV’s ordinary shares are listed in Amsterdam and New York. Trading on the New York Stock Exchange is in the form of American Depositary Shares (ADSs), evidenced by American Depositary Receipts (ADRs) issued by Citibank N.A., as depositary. During 2014, Reed Elsevier Group plc, a UK registered company which ownsincorporated in England, owned the publishing and information businesses and Elsevier Reed Finance BV, a Dutch registered company which ownsincorporated in the Netherlands, oversaw financing and treasury activities. Reed Elsevier PLC and Reed Elsevier NV have retained their separate legal and national identities and are publiclyeach held companies. Reed Elsevier PLC’s securities are listed in London and New York, and Reed Elsevier NV’s securities are listed in Amsterdam and New York.

Equalisation arrangements

Reed Elsevier PLC and Reed Elsevier NV each hold a 50% interest in Reed Elsevier Group plc. Until February 2015, Reed Elsevier PLC holdsheld a 39% interest in Elsevier Reed Finance BV withand Reed Elsevier NV holdingheld a 61% interest. Reed Elsevier PLC additionally holds a 5.8%an indirect equity interest in Reed Elsevier NV, reflecting the arrangements entered into between the two companiesReed Elsevier PLC and Reed Elsevier NV at the time of the merger, which determined the equalisation ratio whereby one Reed Elsevier NV ordinary share is, in broad terms, intended to confer equivalent economic interests to 1.538 Reed Elsevier PLC ordinary shares. The equalisation ratio is subject to change to reflect share splits and similar events that affect the number of outstanding ordinary shares of either Reed Elsevier PLC or Reed Elsevier NV.

Under the equalisation arrangements, Reed Elsevier PLC shareholders have a 52.9% economic interest in Reed Elsevier, and Reed Elsevier NV shareholders (other than Reed Elsevier PLC) have a 47.1% economic interest in Reed Elsevier. Holders of ordinary shares inEffective February 25, 2015, Reed Elsevier PLC and Reed Elsevier NV enjoy substantially equivalent dividend and capital rights with respect totransferred their ordinary shares.

The Boards of both Reed Elsevier PLC and Reed Elsevier NV have agreed, other than in special circumstances, to recommend equivalent gross dividends (including, with respect to the dividend on Reed Elsevier PLC ordinary shares, the associated UK tax credit), based on the equalisation ratio. A Reed Elsevier PLC ordinary share pays dividends in sterling and is subject to UK tax law with respect to dividend and capital rights. A Reed Elsevier NV ordinary share pays dividends in euros and is subject to Dutch tax law with respect to dividend and capital rights.

The principal assets of Reed Elsevier PLC comprise its 50% interest in Reed Elsevier Group plc, its 39% interestdirect ownership interests in Elsevier Reed Finance BV its indirect equity interest in Reed Elsevier NV and certain amounts receivable from subsidiaries of Reed Elsevier Group plc. The principal assets of Reed Elsevier NV comprise its 50% interest into their jointly-owned company Reed Elsevier Group plc its 61% interest in Elsevier Reed Finance BV and certain amounts receivable from subsidiaries ofnamed this newly-combined single group entity RELX Group plc. As a result, RELX Group plc now holds all Reed Elsevier Group plc. Reed Elsevier NV also owns shares, carrying special dividend rights, in Reed Elsevier Overseas BV, a Dutch registered subsidiary of Reed Elsevier Group plc.businesses, subsidiaries and financing activities. Further information is provided on pages 23 to 24.

Material acquisitions and disposals

Total acquisition expenditure in the three years ended December 31, 2013, including the buy out of non-controlling interests,2014, was £1,120£933 million, net of cash acquired of £50£35 million. During 2014, a number of acquisitions were made for total consideration of £396 million, net of cash acquired of £9 million. During 2013, a number of acquisitions were made for total consideration of £239£221 million, net of cash acquired of £14 million. During 2012, a number of acquisitions including the buy out of non-controlling interests, were made for a total consideration of £341£316 million, net of cash acquired of £12 million. During 2011, a number of acquisitions were made for a total consideration of £540 million, net of cash acquired of £24 million.

Total consideration from disposal transactions closed in 2013 was £331 million, including £6 million in respect of freehold properties. The net cash received inon the calendar year from business disposals,disposal of non-strategic assets, after timing differences and separation and transaction costs, was £53 million (2013: £195 million (2012:million; 2012: £160 million; 2011: £80 million).

Capital expenditure

Capital expenditure on property, plant, equipment and internally developed intangible assets principally relates to investment in systems infrastructure to support electronic publishing activities, computer equipment and office facilities. Total such capital expenditure, which was financed using cash flows generated from operations, amounted to £308£270 million in 2013 (2012:2014 (2013: £308 million; 2012: £333 million; 2011: £350 million). In 2013,2014, there was continued investment in new product and related infrastructure, particularly in the Legal segment. Further information on capital expenditure is given in notes 15 and 17 to the combined financial statements.

Principal Executive Offices

The principal executive offices of Reed Elsevier PLC are located at 1-3 Strand, London WC2N 5JR, England. Tel: +44 20 7166 5500. The principal executive offices of Reed Elsevier NV are located at Radarweg 29, 1043 NX Amsterdam, the Netherlands. Tel: +31 20 485 2222. The principal executive office located in the United States is at 125230 Park Avenue, 23rd Floor, New York, New York, 10017.10169. Tel: +1 212 309 8100. Our internet address is www.reedelsevier.com.www.relxgroup.com. The information on our website is not incorporated by reference into this report.

Our agent in the United States is Kenneth Thompson II, General Counsel Intellectual Property, Privacy and Governance, Reed Elsevier, kenneth.thompson@reedelsevier.com,RELX Group, kenneth.thompson@relxgroup.com, 9443 Springboro Pike, B4/F5/514, Miamisburg, Ohio, 45342.

BUSINESS OVERVIEW

Reed Elsevier isWe are a world leading provider of professional information solutions operatingfor professional customers across severalindustries. We operate in four market segments: Scientific, Technical & Medical, providing information and tools to help its customers improve scientific and healthcare outcomes; Risk Solutions,& Business Information, providing data services and tools that combine proprietary, public and third-party information, with advanced technology and analytics; Business Information, providing data services, information and marketing solutionsanalytics to business professionals;and government customers; Legal, providing legal, tax, regulatory news and business information to legal, corporate, government and academic markets; and Exhibitions, organising exhibitions and conferences.

The Group’s reported segments are based on the internal reporting structure and financial information provided to the Boards. During 2014, Risk Solutions and Business Information have been combined into one business area, having previously operated separately. Accordingly, they are now presented as a single operating segment. Comparative figures have been presented as if the businesses had operated on a combined basis in the prior year.

Our principal operations are in North America and Europe. For the year ended December 31, 20132014 we had total revenue of approximately £6.0£5.8 billion and an average of approximately 29,000of28,200 employees. As at December 31, 20132014 we had approximately 28,000had28,500 employees. In 2013,2014, North America represented our largest single geographic market, contributing 51%contributing50% of our total revenue.

Revenue is derived principally from subscriptions, transactional and advertising sales. In 2013, 52%2014, 51% of Reed Elsevier’sour revenue was derived from subscriptions, 44%subscriptions,47% from transactional sales and 4%and2% from advertising sales. An increasing proportion of revenue is derived from electronic information products, principally internet based. In 2013,2014, 66% of our revenue was derived from such sources, including 96%including85% of Risk Solutions revenue, 76%& Business Information revenue,77% of Legal revenue, 72%revenue,74% of Scientific, Technical & Medical revenue, 60% of Business Information revenue, and 2%revenueand3% of Exhibitions revenue.

Subscription sales are defined as revenue derived from the periodic distribution or update of a product or from the provision of access to online services, which is often prepaid. Transactional sales include all other revenue from the distribution of a product and transactions of online services, usually on cash or credit terms. The level of publishing related advertising sales has historically been tied closely to the economic and business investment cycle with changes in the profit performance of advertisers, business confidence and other economic factors having a high correlation with changes in the size of the market. Subscription sales and transactional sales have tended to be more stable than advertising sales through economic cycles.

Revenue is recognised for the various categories as follows: subscriptions — on periodic despatch of subscribed product or rateably over the period of the subscription where performance is not measurable by despatch; transactional — on despatch or occurrence of the transaction or exhibitionexhibition; and advertising — on publication or period of online display. Where sales consist of two or more independent components whose value can be reliably measured, revenue is recognised on each component as it is completed by performance, based on the attribution of relative value.

Our businesses compete for subscription, transactional, and advertising expenditures in scientific and medical, risk, legal and business sectors. The bases of competition include, for readers and users of the information, the quality and variety of the editorial content and data, the quality of the software to derive added value from the information, the timeliness and the price of the products and, for exhibitors and advertisers, the quality and the size of the audiences targeted.

For additional information regarding revenue from our business activities and geographic markets, see note 3 to the combined financial statements contained herein.“Item 5: Operating and Financial Review and Prospects” on page 26.

SCIENTIFIC, TECHNICAL & MEDICAL

In Scientific, Technical & Medical markets, we provide information and tools to help customers improve scientific and healthcare outcomes.

Elsevier is a leading provider of scientific, technical & medical information serving scientists, health professionals and students worldwide. Its objective is to help its customers advance science and improve healthcare by providing world-class content and innovative information solutions that enable them to make critical decisions, enhance productivity and improve outcomes.

Elsevier is a global business with principal operations in Amsterdam, Beijing, Boston, Chennai, Delhi, London, Madrid, Munich, New York, Oxford, Paris, Philadelphia, Rio de Janeiro, St. Louis, San Diego, Singapore and Tokyo. It has 6,7007,000 employees.

In 2013,2014, approximately 67%68% of revenue came from subscription sales, 30% from transactional sales, and 3%2% from advertising. Approximately 38%Approximately37% of revenue by destination in 20132014 was derived from North America, 30%America,30% from Europe and the remaining 32%remaining33% from the rest of the world. 72%world.74% of revenue was delivered electronically.

Elsevier serves the needs of the science, technology & medical markets by publishing primary research, reference, and education content, as well as by providing a range of database and workflow solutions. Elsevier’s customers are scientists, academic institutions, “educators”,educators, research leaders and administrators, medical researchers, doctors, nurses, allied health professionals and students, as well as hospitals, research institutions, health insurers, managed healthcare organisations, research-intensive corporations, and governments. All of these customers rely on Elsevier to provide high-quality content and critical information for making scientific and medical decisions; to review, publish, disseminate and preserve research findings; to create innovative tools to help focus research strategies, increase research effectiveness, improve medical outcomes, and enhance the efficiency of healthcare and healthcare education.

In the primary research market during 2013, over 12014, over1.1 million research papers were submitted to Elsevier. Over 10,00016,000 editors managed the peer review and selection of these papers, resulting in the publication of more than 350,000360,000 articles in over 2,000 journals, many of which are the foremost publications in their field and a primary point of reference for new research. This content was accessed by around 1112 million people, with more than 700750 million full text article downloads in 2013.last year. Content is provided free or at very low cost in most of the world’s poorest countries. Elsevier’s journals are primarily published and delivered through theScienceDirectplatform, the world’s largest database of scientific and medical research, hosting over 12 million pieces of content, and 26,00030,000 full-text e-books. Flagship journals includeCellandThe Lancetfamilies of titles.

In 20132014, Elsevier acquired Mendeley, an innovative research managementexpanded the Lancet collection, adding new titles such as The Lancet Psychiatry, The Lancet HIV and social collaboration platform. Researchers use Mendeley’s desktop and cloud-based tools to manage and annotate documents, create citations and bibliographies, collaborate on research projects and network with fellow academics.The Lancet Haematology.

Elsevier is also a global leader in the scientific, technical & medical reference market, providing authoritative and current professional reference content. While reference has traditionally been aprovided in print, industry, Elsevier has been a leader in driving the shift from print to electronic. Flagship titles include works such asGray’s Anatomy,,Nelson’s PediatricsandNetter’s Atlas of Human Anatomy.Anatomy.

Elsevier launchedElsevier’s flagship clinical reference platform, ClinicalKey,in 2012, providing provides physicians with access to leading Elsevier and third-party reference and evidence-based medical content in a single, fully integrated site.Since launchsite. ClinicalKey has grown rapidly, is continuing to grow, and is currently servesaccessed by over 1,0002,000 institutions.

In medical education, Elsevier serves students of medicine, nursing and allied health professions through print and electronic books, as well as electronic solutions. For example,Evolve, HESI, an online suite of solutionstesting and remediation solution designed to help students of nursing and allied health professionals, hadconducted over 4 million registered users700,000 tests in 2013.2014.

Elsevier’s database and workflow products provide a range of tools and solutions for professionals in the science, technical, and medical fields. Customers include academic and corporate researchers, research administrators and healthcare professionals.

For academic and corporate researchers, significant products includeScopus,,Reaxys,, andKnovel. Knovel. Scopusis the largest abstract and citation database of research literature in the world, with over 5056 million abstract and bibliographic information

records from more than 20,00021,000 peer-reviewed journals and 5,000 international publishers.Reaxysis a leading solution for synthetic chemists, integrating chemical reaction and compound data searching with synthesis planning.

Knovelprovides a range of web-based productivity tools for the engineering community, integrating technical information with analytics and search to deliver trusted answers and drive innovation.

Elsevier serves academic and government research administrators through itsSciValitsElsevier Research Intelligence suite of products that help them evaluate their institutions’ research performance, determine research strategies and increase institutional efficiencies.products. Leveraging bibliometric data such as citations fromScopus, and other data types, SciVal, Spotlighthelps institutions to establish, execute and governments to identify their distinctiveevaluate research strengths, evaluatestrategies. Pure is a comprehensive research information management system which enables evidence-based research management decisions, promotes collaboration, simplifies administration and optimises impact. Our Analytical Services team provides accurate, unbiased analysis on research performance by combining high quality data sources with technical and increase the focus of their research and development investments.metrics expertise. SciVal Fundingassists researchers and institutions in identifying grants that are most relevant in their research areas.

For healthcare professionals, Elsevier develops products to deliver patient-specific solutions at the point of care to improve patient outcomes. Its clinical solutions includeGold Standard, ExitCare which provides criticalpatient education and discharge information on drug interactions to assist effective treatment andCPM Resource Center,, which provides a data-driven framework to support nurses in undertaking procedures.

Market opportunities

Scientific, technical & medical information markets have good long-term growth characteristics. The importance of research and development to economic performance and competitive positioning is well understood by governments, academic institutions and corporations. This is reflected in the long-term growth in research and development spend and in the number of researchers worldwide. Growth in health markets is driven by ageing populations in developed markets, rising prosperity in developing markets and the increasing focus on improving medical outcomes and efficiency. Given that a significant proportion of scientific research and healthcare is funded directly or indirectly by governments, spending is influenced by governmental budgetary considerations. The commitment to research and health provision does, however, remain high, even in more difficult budgetary environments.

Strategic priorities

Elsevier’s strategic goal is to lead the way in providing information solutions that advance science, technology and health. To achieve this, Elsevier creates solutions that reflect deep insight into the way its users work and the outcomes they are seeking to achieve; strives for excellence in content, service and execution; constantly adapts and revitalises its products, business models and technology; and leverages its institutional skills, assets and resources to promote innovation and efficiency.

Elsevier’s strategic priorities are to continue to increase content volume and quality; to expand content coverage, building out integrated solutions combining Elsevier, third-party and customer data; to increase content utility, using “Smart Content” to enable new e-solutions; to combine content with analytics and technology, focused on measurably improving productivity and outcomes for customers; and to continue to drive operational efficiency and effectiveness.

In the primary research market, Elsevier aims to grow volume through new journal launches, expansion of author-pays journals and growth from emerging markets; to enhance quality by building on our premium brands; and to add value to core platforms by implementing new capabilities such as advanced recommendations onScienceDirectand social collaboration through Mendeley.

In clinical reference markets, priorities are to expand content coverage, including licensing high-quality third-party content forClinicalKey,, as well as ensuring consistent tagging to link content assets across products.

Business model, distribution channels and competition

Science and medical research is principally disseminated on a paid subscription basis to the research facilities of academic institutions, government and corporations, and, in the case of medical and healthcare journals, also to individual practitioners and medical society members. For a number of journals, advertising and promotional income represents a small proportion of revenues predominantly from pharmaceutical companies in healthcare titles.

Over the past 15 years alternative payment models for the dissemination of research such as “author-pays open access”“author-pays” or “author’s-funder-pays”“author’s-funder-pays” have emerged. While it is expected that paid subscription will remain the primary distribution model, Elsevier has long invested in alternate business models to address the needs of customers and researchers. Over 1,600 of Elsevier’s journals now offer the option of funding research publishing and distribution via a sponsored article fee. In addition, Elsevier now publishes more than 50100 open access journals.

Electronic products, such asScienceDirect,,ScopusandClinicalKey,, are generally sold direct to customers through a dedicated sales force that has offices around the world. Subscription agents facilitate the sales and administrative process for print journals. Books are sold through traditional and online book stores, wholesalers and, particularly in medical and healthcare markets, directly to end users.

Competition within science and medical publishing is generally on a title-by-title and product-by-product basis. Competing journals, books and databases are typically published by learned societies and other professional publishers. Workflow tools face similar competition, as well as from software companies and internal solutions developed by customers.

Major brands

Elsevier is the master brand used for the business.

Elsevier’s major brands include:Cell,, a life sciences journal in biochemistry and molecular biology; andThe Lancet,, one of the world’s leading medical journals since 1823. Many other products and journals are major brands in their fields, including: Mendeley,, an innovative research management and social collaboration platform;SciVal,, ready-to-use tools to analyse the world of research, performance toolsand establish, execute and evaluate the best strategies for academic institutions and funding intelligence;Reaxys,a leading web-based chemical reaction workflow solution for industrial chemists;research organisations; ClinicalKey,combines reference and evidence-based medical content into its fully-integrated clinical insight engine;ScienceDirect,the world’s largest database of scientific and medical research articles; andCPM CarePoints,Scopus, a leading comprehensive care planningresearch performance tool for academic institutions and clinical documentation system.funding intelligence; and HESI, a suite of preparation testing and remediation resources that generate actionable data to prepare nursing and health profession students for success in pursuing degrees, passing licensure exams and starting their careers.

RISK SOLUTIONS & BUSINESS INFORMATION

In Risk Solutions & Business Information, we provide data, analytics and insight that enable customers to evaluate and manage risk, andrisk. We develop market intelligence, supporting more confident decisions, improvedimproving economic outcomes, and enhancedenhancing operational efficiency.

RISK SOLUTIONS

From 2014 Risk Solutions and Business Information have been combined into one business area. This union brings together LexisNexis Risk Solutions is a leading provider of solutions that combineSolutions’ proprietary, public and third-party information, with advanced technology and analytics, with Reed Business Information’s high-value industry critical data services, information and are powered by High Performance Computing Cluster (HPCC) Systems. These solutions assist customers in evaluating, predictingtools as well as conferences, websites and managing risk and improving operational effectiveness, predominantly in the US.business magazines.

LexisNexis Risk Solutions, headquartered in Alpharetta, Georgia,& Business Information has principal operations in Georgia, Florida, Illinois and Ohio in the US and London, Amsterdam and Shanghai. Risk & Business Information has 3,3007,400 employees.

In 2013, approximately 84% Approximately 73% of revenue in 2014 came from North America, 22% from Europe and 5% from the rest of the world. 85% of Risk Solutions’& Business Information’s revenue came from transactional sales and 16% from subscription sales. 96% of Risk Solutions’ revenue iswas delivered electronically.

LexisNexis Risk Solutions& Business Information is organised around market-facing industry/sector groups:groups including insurance, business services, government, healthcare, major data services (including the financial services, receivables managementbanking, energy and corporate groups), governmentchemicals, human resources) and healthcare.other leading brands. The largest of these sector groups is insurance. These groups are supported by a shared infrastructure for technology operations, data

The identity management and other support functions including compliancerisk evaluation solutions provided by Insurance Solutions, Business Services, Government Solutions and marketing. A numberHealth Care Solutions utilise comprehensive database platforms of transactional support activities, including some financial processes, are provided from a shared services organisation managed bypublic records and proprietary information with more than two petabytes of unique data, which makes it the LexisNexis Legal & Professional business. The Legal & Professional business also distributes Risk Solutions products into legal marketslargest database of its kind in the US market today. Our market-leading technology enables Risk & Business Information to provide its customers with highly relevant search results swiftly and internationally.to create new, low-cost solutions quickly and efficiently. It is also increasingly used across other Group business areas such as Legal and Scientific, Technical & Medical.

Risk & Business Information is focused on developing a pipeline of new solutions to drive growth in existing business segments and selected adjacent markets and geographies.

Insurance Solutions provides a comprehensive combination of data and analytics to property and casualty, personal, and commercial lines insurance carriers and life insurance carriers in the US to improve critical aspects of their business, from customer acquisition and underwriting to claims handling. Information solutions, including the most comprehensive US personal loss history database,C.L.U.E.^®, help

insurers assess risks and provide important inputs to pricing and underwriting insurance policies. Additional key products includeLexisNexis^® Data Prefill,, which provides critical information on customers, potential customers and their auto, property and life policy information directly into the insurance workflow, andLexisNexis^® Current Carrier,, which identifies current or previous insurance coverage details as well as any lapses in coverage. Insurance Solutions released new driving behaviour products in four states in 2014. These products aggregate court data within specific states to provide insurers with vital traffic violation information for use in underwriting. In the UK, Insurance Solutions’ contributory No Claims Discount (NCD) module, which automates verification of consumers’ claims history, has achieved data contribution from over 55% of the UK auto insurance sector in just over a year.

In the Insurance business, Risk & Business Information acquired four businesses during 2014. Wunelli is an industry-leading telematics data services company based in the United Kingdom. The combined LexisNexis and Wunelli datasets will result in one of the largest provider-held insurance telematics databases in the world, with solutions to support insurers as they assess risk and discount safer drivers. Risk & Business Information also acquired three US based businesses to enhance the LexisNexis eCrash solution. iyeTek is an innovative provider of mobile and handheld software solutions, enabling public safety agencies to save time and money and improve services provided to their communities. PoliceReports.US is an online distributor of vehicle accident reports currently in use by 29 states and Coplogic is a leading provider of citizen self-reporting software solutions to law enforcement agencies. In October, a joint venture was signed with Jing You to supply data into the fast-growing auto insurance market in China.

Business Services provides financial institutions with risk management, identity management, fraud detection, credit risk management, and compliance solutions. These include “know your customer”Know Your Customer and anti-money laundering (“AML”)Anti-Money Laundering products. The business also provides risk and identity management solutions for corporate customers in retail, telecommunications and utilities sectors. Receivables management solutions help debt recovery professionals in the segmentation, management and collection of consumer and business debt.

In Business Services, Risk & Business Information acquired Tracesmart, a United Kingdom-based provider of tracing, identity verification, fraud prevention, Anti-Money Laundering, debt collection and data cleansing solutions. Tracesmart, a leader in identity management and fraud solutions in the UK, is a natural complement to Risk & Business Information’s core competencies and brings a robust set of UK public records, allowing Risk & Business Information to extend its capabilities beyond the US in order to serve its customers more fully.

Government Solutions provides data and analytics to US federal, state and local law enforcement and government agencies to help solve criminal and intelligence cases and to identify fraud, waste and abuse in government programmes. The group’s Tax Refund Investigative Solution (TRIS), now sold into eight states and the District of Columbia, continues to generate substantial benefits for both clients and taxpayers, with results to date over $100 million in avoided fraud losses.

Health Care Solutions provides identity, fraud, and clinical analytics solutions across key stages of thehealthcareworkflowthe healthcare workflow to enable intelligent decision making for payers and providers.

During the year, the acquisition of Health Market Science, a leading supplier of high-quality data on healthcare professionals and an administrator of one of the largest practitioner-level medical claim databases in the US, was completed.

The LexisNexis Risk Solutions business also provides risk-related information to the legal industry through LexisNexis Legal & Professional.

LexisNexisOutside of these areas, Risk Solutions continues& Business Information provides information and online data services to focus on developingbusiness professionals worldwide, with high-value industry critical data services, information and tools as well as producing conferences, websites and business magazines. It has many strong global brands with market-leading positions across a pipelinewide range of newindustry sectors.

Data Services include: ICIS, an information and data service in chemicals, energy and fertiliser; Accuity, a provider of services and solutions to drive growth in existing business segmentsthe banking and selected adjacent marketscorporate sectors focused on payment efficiency, Know Your Customer, Anti-Money Laundering and geographies. In 2013,this strategy was reinforced with a numbercompliance; and XpertHR, an online service providing regulatory guidance, best practices and tools for HR professionals. During the year, Accuity completed the acquisition of focused acquisitions.

In the Insurance business, LexisNexis Risk Solutions acquired Mapflow, an industry-leading geographic risk assessment technology company based in Dublin, Ireland. Mapflow’s technology combined with Risk Solutions’ comprehensive data, advanced analytics, supercomputing platform (HPCC Systems) and linking capabilities help commercial and home insurers better understand property-level geographic peril risk to make more informed underwriting decisions.

In Business Services, LexisNexis Risk Solutions acquired the remaining stake in WorldCompliance,FircoSoft, a leading provider of customerwatch list filtering solutions for financial institutions and vendor screening content,corporates. Accuity also launched risk solutions for customers in trade finance.

Leading Brands include Flightglobal, Farmers Weekly, Boerderij, Fiscaal Totaal, Estates Gazette, Elsevier and New Scientist and deliver a mix of high quality data, workflow tools and high-value news, information and opinion to complement our existing AML and compliance solutions. LexisNexis Risk Solutionsbusiness professionals across many industry sectors while also acquired RSA Security’s consumer Knowledge Based Authentication technology to drive further innovation and strengthen its leadership position in identity management. In Health Care,providing an effective marketing channel for customers. During the year Flightglobal completed the acquisition of Enclarity supplements the existing identityInnovata, a provider of global airline schedules data. Risk & Business Information also acquired Farmade, a UK-based supplier of crop recording, mapping and fraud, waste, and abuse solutions with the most comprehensiveprecision farming workflow tools.

In 2014, Risk & Business Information continued to reshape its portfolio, exiting areas not core to its strategy. As part of this strategy, 51% of Reed Construction Data (RCD), a provider information available. The transition of MEDai from Elsevier to Risk Solutions’ Health Care business was announced, enabling the combination of MEDai’s clinical expertise with Risk Solutions’ analytics,online construction data and HPCC technologyinformation to create leading clinical analytics solutions.

The identity managementthe construction industry was divested, and risk evaluation solutions provided by100% of RS Means, a construction costing service which had previously been a division of RCD. Risk & Business Information also completed its exit from its Marketing Solutions utilise comprehensive database platformsbusinesses, including the sales of public recordsBuyerZone and proprietary information with more than 2 petabytesemedia and one divestment of unique data, which makes it the largest databasea portfolio of B2B assets from its kind in the US market today.LexisNexis Accurintis a flagship product, powered by the HPCC technology. Thismarket-leading technology enables LexisNexis Risk Solutions to provide its customers with highly relevant search results swiftly and to create new, low-cost solutions quickly and efficiently. It isNetherlands operation now also increasingly used across other Reed Elsevier markets such as Legal and Scientific, Technical & Medical.

In February 2013, Risk Solutions completed the sale of its Screening business. This allows it to increase its focus onhigher-growth segments leveraging its core data, technology and analytical capabilities. The Screening business presented limited opportunities to apply these capabilities to generate unique customer value, sustained growth, and superior margins.completed.

Market opportunities

Risk Solutions& Business Information operates in markets with strong long-term underlying growth drivers with growing demand for high-quality industry data and information and insight including: insurance underwriting transactions; insurance, healthcare, tax and entitlement fraud; credit defaults and financial fraud; regulatory compliance and due diligence requirements surrounding customer enrolment; and security and privacy considerations.considerations; and data and analytics for the banking, energy and chemicals, human resources and aviation sectors.

In the insurance segment, growth is supported by increasing transactional activity in the auto, property and life insurance markets and the increasing adoption by insurance carriers of more sophisticated data and analytics in the prospecting, underwriting and claims evaluation processes, to assess underwriting risk, increase competitiveness and improve operating cost efficiency. Transactional activity is driven by growth in insurance quoting and policy switching, as consumers seek better policy terms. This activity is stimulated by increasing competition betweenamong insurance companies, high levels of carrier advertising, and rising levels of internet quoting and policy binding.

A number of factors support growth for risk solutions in thebanking and financial services market,markets, including cross-border payments and trade finance levels, new credit originations, continued high fraud losses, stringent regulatory compliance requirements, and increasing anti-money launderingAnti-Money Laundering fines. In receivables management, demand is driven mainly by levels of consumer debt and the prospect of recovering that debt, which is impacted by employment conditions in the US. In corporate markets, demand is supported by growth in online retail sales and continued high levels of credit card fraud. Growth in government markets is driven by the increasing use of data and analytics to combat criminal activity, fraud and tax evasion, and to address security issues. The level and timing of demand in this market is influenced by government funding and revenue considerations. In Health Care, there are numerous growth drivers for fraud and analytics solutions including the expansion of insurance coverage under the Affordable Care Act and the focus on cost containment and better patient outcomes.

Growth in the global energy and chemicals markets is driven by increasing trade and demand for more sophisticated information solutions. Risk & Business Information’s aviation information markets are being driven by increases in air traffic and in the number of aircraft transactions.

Strategic priorities

Risk Solutions’& Business Information’s strategic goal is to makehelp businesses and government more effective,achieve better outcomes with information and decision support in its individual markets through a better understanding of the risks associated with individuals, other businesses and transactions and bytransactions. By providing the highest quality industry data and tools, to help

manage thosewe assist customers in understanding their markets and managing risks efficiently and cost effectively. To achieve this, Risk Solutions& Business Information is focused on: delivering innovative new products across customer workflows; expanding the range of risk management solutions across adjacent markets; addressing international opportunities in selected markets to meet local risk management needs; further growing its data services businesses; and continuing to strengthen its content, technology, and analytical capabilities.

Business model, distribution channels and competition

LexisNexis Risk Solutions’& Business Information’s products in Insurance, Business Services and Government are predominantlyfor the most part sold directly, with pricing mostlypredominantly on a transactional basis for insurance carriers and corporations, and primarily on a subscription basis for government entities.

LexisNexis Data services are typically sold directly on a subscription or transactional basis. Business magazines are mainly distributed on a paid basis. Advertising revenues are sold directly.

Risk Solutions& Business Information and Verisk, a competitor, each sell data and analytics solutions to insurance carriers but largely address different activities. LexisNexis Risk Solutions’& Business Information’s principal competitors in commercialbusiness services and government sectorssegments include Thomson Reuters and major credit bureaus, which in many cases address different activities in these segments as well.

Risk & Business Information’s data services and leading brands compete with a number of information providers on a service and title-by-title basis including: Platts, Thomson Reuters, IHS and Wolters Kluwer as well as many niche and privately owned competitors. Risk & Business Information competes for online advertising with other business-to-business websites, search engines and social media.

Across Risk & Business Information, subscription revenues now account for 94% of the total business with the remaining 6% derived from print and online advertising.

Major brands

LexisNexis is the master brand used by LexisNexis Risk Solutions.

LexisNexis Risk Solutions’& Business Information’s major brands include:C.L.U.E. C.L.U.E.^®, a comprehensive US personal insurance claims database;LexisNexis^®Data Prefill,, tools to automate the insurance application process providing critical information insurers need to quote and underwrite a policy;Accurint LexisNexis^® for Collections, a leading online US solution to help locate debtors quickly and accurately; LexisNexis^® Identity Management,, a range of solutions to help clients verify that an identity exists and authenticate individuals;LexisNexis^® Anti-Money Laundering Solutions,, content and information for anti-money laundering compliance, risk mitigation and enhanced due diligence;LexisNexis^® Current Carrier,database that identifies the existence of current or previous insurance, and whether or not the applicant has had a possible lapse in coverage;LexisNexis^® RiskView,comprehensive suite of credit risk management tools to help assess consumer creditworthiness and risk potential; andLexisNexis^® Revenue Recovery and Discovery,a suite of tools to enable governments to leverage public records and analytics to identify instances of fraud and to more efficiently collect on outstanding debts.

BUSINESS INFORMATION